
Burlingame, California-based Tallac Therapeutics Inc, a biopharmaceutical company focused on fighting cancer, has raised $62 million in Series A financing. The backers included venBio Partners, Morningside Venture, Lightstone Ventures, Matrix Partners China, and MRL Ventures Fund.
Source: Press Release